Navigation Links
Cognition Therapeutics Closes Series A Financing to Advance Drug Candidates for Alzheimer's Disease
Date:7/16/2009

PITTSBURGH, July 16 /PRNewswire/ -- Cognition Therapeutics Inc., a Pittsburgh-based drug discovery company developing small molecule disease-modifying treatments for Alzheimer's, has closed on a $1.21M Series A financing. The round was led by Ogden CAP, LLC of New York City and includes M5Invest Partners of Villanova, PA, the Pittsburgh Life Sciences Greenhouse, Innovation Works (Pittsburgh), and several individual investors. The round included both new investments and the conversion of existing convertible notes.

"This investment facilitates the advancement of our existing lead molecules towards a major milestone," said Cognition Therapeutics President and CEO Hank Safferstein, Ph.D., J.D. "Our combination of novel, small molecule drug candidates and biologically-relevant screening methods is unique in the pharmaceutical industry. We're pleased to have Ogden CAP and M5Invest join our other investors in supporting our pioneering approach to treat or prevent Alzheimer's disease by targeting the proteins that cause the earliest stages of this disease".

"As early investors, we are impressed by Cognition Therapeutics' combination of cutting-edge technology, influential and experienced leadership, and large clinical and commercial potential," said Robert Gailus, senior advisor to Ogden CAP. "Alzheimer's disease is a major health epidemic that places increasing strains on the world's healthcare systems as the population ages. The drug candidates being developed by Cognition have the potential to significantly impact this devastating disease," Gailus continued. Alzheimer's disease affects an estimated four and a half million people in the United States today. That number is expected to exceed 12 million people by 2050.

Funds raised in this round will support advancement of Cognition Therapeutics' pioneering lead molecules that block the activity of the toxic oligom
'/>"/>

SOURCE Cognition Therapeutics Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. New Evidence That Brain-Plasticity Based Training has Broad Impact: Improved Cognition in Boomers, Improved Motor Control in Older Adults
2. ExonHits EHT 0202 Counters Scopolamines Detrimental Effects on Cognition in Humans
3. Intra-Cellular Therapies Presents Data on Its Schizophrenia and Cognition in Schizophrenia Programs at the 14th Biennial Winter Workshop on Schizophrenia and Bipolar Disorders
4. Calixa Therapeutics Announces Initiation of Phase 2 Clinical Trial of Its Antibiotic, CXA-101, in Patients with Complicated Urinary Tract Infections
5. Vantia Therapeutics Lead Candidate VA106483 Demonstrates Positive Anti-diuretic Effect in Phase IIa Trial in Nocturia
6. Amicus Therapeutics Commences Phase 3 Trial Evaluating Amigal(TM) for the Treatment of Fabry Disease
7. Horizon Therapeutics HZT-501 Significantly Reduces Incidence of NSAID-Induced Upper Gastrointestinal Ulcers in Patients With Mild-to-Moderate Pain
8. InteKrin Therapeutics to Present at the 2009 American Diabetes Association Annual Meeting
9. Fate Therapeutics Announces First Patient Treated in Phase 1b Clinical Trial of FT1050 for Hematopoietic Stem Cell Support
10. Ascenta Therapeutics Announces Multiple Presentations on AT-101 at 2009 ASCO Annual Meeting
11. Oxford BioTherapeutics and GlaxoSmithKline Form Strategic Alliance to Develop Novel Cancer Therapeutic Antibodies

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2009)... CHICAGO,Nov.27/PRNewswire/--AttheupcomingRadiolog...ngSunday,RoyalPhilipsElectronics(PHG,AEX:PHI)willd...cssolutionsdesignedtodirectlyaddresstheprioritieso...aginginnovationsthatreflectadesireforvalue,modular...ePhilipstoprovidecontinuedaccesstoadvancedtechnolo...
(Date:11/25/2009)... LOVELAND,Colo.,Nov.25/PRNewswire-FirstCall/--Hesk...dvanceddiagnosticandspecialtyproductstotheveterina...sticsCorporationforthesupplyofbloodgasproductsanda...(Logo: http://www.newscom.com/cgi-bin/prnh/2000062...ionforinnovatinginthefieldofadvancedpoint-of-cared...
(Date:11/25/2009)... CHICAGOandSTAFA,Switzerland,Nov.25/PRNewswire/-- ...nnovativehearingsolutions,presentedthesecondeditio...specialneedsoftheolderpopulation.Theconferencebrou...oundtheworldandmorethan250clinicianswhoworkeveryda...hareexperiencesanddiscussthelatestresearchandtrend...
Breaking Medicine Technology:Philips Helps Hospitals Strike Balance Between Innovation and Value 2Philips Helps Hospitals Strike Balance Between Innovation and Value 3Philips Helps Hospitals Strike Balance Between Innovation and Value 4Heska Announces Supply Agreement With Roche Diagnostics 2Heska Announces Supply Agreement With Roche Diagnostics 3Phonak Successfully Hosts Hearing Care for Adults 2009 Conference 2Phonak Successfully Hosts Hearing Care for Adults 2009 Conference 3Healthcare Trust of America Inc Executes Agreement to Acquire a 108 500 SF Medical Office Building Located in Spartanburg South Carolina 61272 1Healthcare Trust of America Inc Executes Agreement to Acquire a 108 500 SF Medical Office Building Located in Spartanburg South Carolina 61272 2Bioniche Pharma Acquires Duraclon 28R 29 28clonidine hydrochloride injection 29 and Methadone Hydrochloride Injection USP 61269 1Bioniche Pharma Acquires Duraclon 28R 29 28clonidine hydrochloride injection 29 and Methadone Hydrochloride Injection USP 61269 2Hollis Eden to Present Interim Data From Its Phase I II Clinical Studies of Apoptone 28R 29 28HE3235 29 at Molecular Targets and Cancer Therapeutics 14819 1Hollis Eden to Present Interim Data From Its Phase I II Clinical Studies of Apoptone 28R 29 28HE3235 29 at Molecular Targets and Cancer Therapeutics 14819 2Hollis Eden to Present Interim Data From Its Phase I II Clinical Studies of Apoptone 28R 29 28HE3235 29 at Molecular Targets and Cancer Therapeutics 14819 3Hollis Eden to Present Interim Data From Its Phase I II Clinical Studies of Apoptone 28R 29 28HE3235 29 at Molecular Targets and Cancer Therapeutics 14819 4Hollis Eden to Present Interim Data From Its Phase I II Clinical Studies of Apoptone 28R 29 28HE3235 29 at Molecular Targets and Cancer Therapeutics 14819 5
... Calif., Oct. 3 Anthera Pharmaceuticals,Inc., a p...,anti-inflammatory therapeutics for chronic and ac...letion of enrollment and patient dosing in its,Pha...or stable coronary,artery disease. Data analysis i.... "We are pleased with the rapid enrollment of th...
...ead Use of Home Blood Pressure Monitoring Becomes ...ands to Include Critical Patients, Microlife Manu... Proven Accuracy (Severe arterial-sclerosis in ...Since the release of the American,Heart Associatio... in 2005,more and more physicians and patients are...
Other Medicine Technology:Anthera Announces Completion of Enrollment and Dosing in Phase II Trial of A-002 for the Treatment of Cardiovascular Disease 2Anthera Announces Completion of Enrollment and Dosing in Phase II Trial of A-002 for the Treatment of Cardiovascular Disease 3Microlife's Home Blood Pressure Monitors Proven Accurate Even for Critical Patients 2Microlife's Home Blood Pressure Monitors Proven Accurate Even for Critical Patients 3
(Date:11/25/2009)...swire/--TheBartleHallConventionCenterwilltemporari...whenKansasCityhoststhelatestinaseriesofmassivefree...enthasthepotentialtobethebiggestoneyet,becauseitwi...daysinsteadofoveraweekend,"SheriWood,executivedire...heNationalAssociationofFreeClinics(NAFC). ,, At...
(Date:11/25/2009)...Newswire/-SentinelleMedicalInc.,aleadingmanufactur...ndCalgaryScientificInc.,aleadingproviderofsoftware...gis(TM)Breast4DAdvancedVisualizationsoftware. ,...rintWebclientbasedmedicalimagingofferinginthemarke...ero-footprintaccess-requiringnosoftwaredownload,an...
(Date:11/25/2009)...ewswire/--Thanksgivingmealswillbedeliveredtoapprox...reathankstoFaithInAction/VolunteerActionforAging,a...ofSCANHealthPlan.Formorethan17yearstheseorganizati...anksgivingmealstoseniorsinneedinLongBeach,Lakewood...cities. ,, "Ourwarmholidaymealsaredeliveredtope...
(Date:11/25/2009)...e-USNewswire/--TheBlackAIDSInstituterecentlyheldBo...ipfor2010. ,, ThenewBoardMembersareahighlydiver...finance,governmenthealthprograms,editorial,andbusi...geofpersonalbackgroundsincludingbothheterosexualan...ndrepresentingmultipleagegroups. ,, (Photo: htt...
(Date:11/25/2009)...,Business,andPressJoinEfforttoEducate ,, MEMPH...theNationalBipolarFoundationandtheMedicAlertFounda...ble"program,whichisnowbeingwidelyacceptedasapreven...ationalBipolarFoundationreceivedaproclamationofend...ernorofLouisianaMitchLandrieu.TheNationalBipolarFo...
Breaking Medicine News(10 mins):Health News:Kansas City Prepares for Largest Free Health Clinic 2Health News:Sentinelle Medical Inc. Introduces Aegis(TM) Web Powered By Calgary Scientific's PureWeb Technology 2Health News:Sentinelle Medical Inc. Introduces Aegis(TM) Web Powered By Calgary Scientific's PureWeb Technology 3Health News:SCAN Employees and Community Volunteers to Help Deliver One Thousand Thanksgiving Meals to Homebound Seniors 2Health News:Black AIDS Institute Announces 2010 Board Election Results 2Health News:First Time-Door is Open for Family Discussion of Bipolar Disorder 2Health News:First Time-Door is Open for Family Discussion of Bipolar Disorder 3
... public’s notice that fluoride in water causes dis...rotect// the teeth from cavities. But now Dr. Ches...d that fluoridated tap water pose a great risk of ...tor of the Colgate Oral Care Report, a newsletter ...
...ly to experience depression, according to a new st...assachusetts General Hospital monitored about 460 ...ho suffered the most hormonal imbalances were pron...en were prone to suffer from depression when they ...
...nsferred to cats. It has been found that cats that...5N1 virus. Scientists from Erasmus Medical C.... The first incidence of domestic cats dying...cass on a farm where there was an outbreak of the ...
...he manufacturers of a new vaccine for anthrax for ...ness// of the vaccine. VaxGen Inc was accused of i...ta for which is not enough for issuing such statem...ity." The promotional also claimed that the vaccin...
... the drive kick started by Ulster's first hospital...ver it takes// to create awareness of the new age ...st, flagged off a pilot programme for 12 weeks tha...ht but also maintained the weight loss. If this pr...
...ralia to stop the misuse and stocking up of the co...omatically// via text messages alerting them to th...rugs at pharmacies. In this new online program eac...ce. Then their details will be stored on an on...
Other Medicine News:
Perforated Conformer (Small 20mm)
...tra-thin collarette conforms to natural anatomy of...d on disposable inserter/dilator instrument for ea...Slim Mini and Slim Petite plugs offer a slightly s...re made of the same clear and polished silicone as...
Lacrimal Probe - Disposable
Ritleng Probe
Medicine Products: